4-Chloro-5-(hexylamino)-2-phenylpyridazin-3(2H)-one | 923027-34-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-Chloro-5-(hexylamino)-2-phenylpyridazin-3(2H)-one
• 英文别名: 4-chloro-5-(hexylamino)-2-phenylpyridazin-3-one
• CAS: 923027-34-3
• 化学式: C₁₆H₂₀ClN₃O
• 分子量: 305.8
• InChiKey: DSGCPZBUGQFRIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Compounds for the Treatment of Neurodegeneration and Stroke
  申请人：Hergenrother J. Paul

  公开号：US20070032496A1

  公开（公告）日：2007-02-08

  Compounds and related methods for synthesis, and the use of compounds for the treatment of neurodegenerative diseases are disclosed. Compounds are disclosed in connection with PARG and/or PARP inhibition. Therapeutic applications are relevant for preventing or inhibiting neurological cell death for a variety of neurodegenerative conditions including Parkinson's disease, ischemia, and stroke. Also disclosed is a high-throughput screen for identifying compounds capable of inhibiting PARG and/or PARP.

  揭示了用于合成的化合物及相关方法，以及用于治疗神经退行性疾病的化合物的使用。这些化合物与PARG和/或PARP抑制有关。治疗应用于预防或抑制多种神经退行性疾病，包括帕金森病、缺血和中风等神经细胞死亡。还揭示了一种用于识别能够抑制PARG和/或PARP的化合物的高通量筛选方法。
• [EN] COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATION AND STROKE<br/>[FR] COMPOSES POUR LE TRAITEMENT DE NEURODEGENERESCENCE ET D'ACCIDENT CEREBRO-VASCULAIRE
  申请人：UNIV ILLINOIS

  公开号：WO2007014226A2

  公开（公告）日：2007-02-01

  [EN] Compounds and related methods for synthesis, and the use of compounds for the treatment of neurodegenerative diseases are disclosed. Compounds are disclosed in connection with PARG and/or PARP inhibition. Therapeutic applications are relevant for preventing or inhibiting neurological cell death for a variety of neurodegenerative conditions including Parkinson's disease, ischemia, and stroke. Also disclosed is a high-throughput screen for identifying compounds capable of inhibiting PARG and/or PARP.
  [FR] La présente invention a trait à des composés et des procédés de synthèse associés, et à l'utilisation de ces composés pour le traitement de maladies neurodégénératives. L'invention a trait à des composés associés à l'inhibition de poly(ADP-ribose) glycohydrolase (PARG) et/ou de poly(ADP-ribose) polymérase (PARP). Des applications thérapeutiques concernent la prévention ou l'inhibition de la mort de cellules neurologique pour diverses conditions neurodégénératives comprenant la maladie de Parkinson, l'ischémie, et l'accident cérébro-vasculaire. L'invention a également trait à un criblage à haute efficacité pour l'identification de composés capables d'inhiber la PARG et/ou la PARP.